Document Detail


The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial.
MedLine Citation:
PMID:  19501395     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study has developed a chitosan-based delivery system to locally administer ellagic acid for brain cancer treatment. We fabricated chitosan/ellagic acid composite films with various concentrations of ellagic acid. In vitro release study was performed by using a UV spectrophotometer, and enzymatic degradation rate was determined by analyzing the increased free amino groups. Viability of brain cancer cells (human U87 glioblastomas and rat C6 glioma cells) was measured via direct and indirect cell culture on the films by MTS assay. Caspase-3 activation, Western blot for p53, and anti-angiogenesis assays were also examined. In the in vivo study, GFP-tagged rat C6 glioma cells were implanted subcutaneously at the right flank region of nude mice and treatments were initiated by implanting the films subcutaneously. Tumor growth was evaluated by measuring tumor volume using a caliper, an ultrasound machine, and an optical imaging system. The chitosan/ellagic acid composite films were enzymatically degradable and exhibited a sustained slow release of ellagic acid. These materials could inhibit the cancer cell growth in an ellagic acid concentration-dependent manner by inducing apoptosis of cancer cells as well as suppressing angiogenesis. These materials also significantly suppressed tumor tissue growth in vivo.
Authors:
Sungwoo Kim; Mostafa W Gaber; Janice A Zawaski; Feng Zhang; Mekel Richardson; Xin A Zhang; Yunzhi Yang
Related Documents :
15844285 - Automorphosis of etiolated pea seedlings in space is simulated by a three-dimensional ...
21744115 - Understanding the influence of phosphatidylcholine on the molecular weight of hyaluroni...
6820625 - Development of aspergillus parasiticus and formation of aflatoxin b1 under the influenc...
15158515 - Allelopathic potential of citrus junos fruit waste from food processing industry.
6667475 - Hydrolytic release, and identification by g.l.c.-m.s., of 3-deoxy-d-manno-2-octulosonic...
20118605 - Evidence for avt6 as a vacuolar exporter of acidic amino acids in saccharomyces cerevis...
Publication Detail:
Type:  Journal Article     Date:  2009-06-05
Journal Detail:
Title:  Biomaterials     Volume:  30     ISSN:  1878-5905     ISO Abbreviation:  Biomaterials     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8100316     Medline TA:  Biomaterials     Country:  England    
Other Details:
Languages:  eng     Pagination:  4743-51     Citation Subset:  IM    
Affiliation:
School of Biomedical Engineering and Imaging, University of Tennessee Health Science Center, Memphis, TN 31863, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Biocompatible Materials / pharmacology*
Blotting, Western
Caspase 3 / metabolism
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Chitosan / pharmacology*
Drug Screening Assays, Antitumor
Ellagic Acid / pharmacology*
Enzyme Activation / drug effects
Female
Glioma / enzymology,  pathology*,  therapy
Humans
Mice
Mice, Nude
Muramidase / metabolism
Neovascularization, Physiologic / drug effects
Rats
Tumor Suppressor Protein p53 / metabolism
Chemical
Reg. No./Substance:
0/Biocompatible Materials; 0/Tumor Suppressor Protein p53; 476-66-4/Ellagic Acid; 9012-76-4/Chitosan; EC 3.2.1.17/Muramidase; EC 3.4.22.-/Caspase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of sperm treatment on efficiency of EGFP-expressing porcine embryos produced by ICSI-SMGT.
Next Document:  Electrophysiological characterization of embryonic hippocampal neurons cultured in a 3D collagen hyd...